NeuroHealing and Coma Science Group Announce Treatment of First Patient in Clinical Trial on Promising Drug for Recovery of Consciousness

Waban, Massachusetts, and Liège, Belgium (Dec 05, 2018) – NeuroHealingPharmaceuticals and the Coma Science Group at the GIGA-Consciousness,University of Liege announce the treatment of the first patient in theclinical trial: “Treating severe brain-injured patients withapomorphine: a behavioral and neuroimaging study. The study (ClinicalTrials.gov Identifier: NCT03623828, EudraCTIdentifier 2018-003144-23) will investigate the effects ofsubcutaneously administered apomorphine in…

Details
NeuroHealing

NeuroHealing Invited to Present at ‘Strategic Partnerships in Drug Repurposing’ Conference

Newton, Massachusetts – October 2016. NeuroHealing Pharmaceuticals, a private, clinical stage company developing innovative drug treatments for specialty indications based on repositioning neurologically active compounds announces the presentation of a case study entitled “A Comparison of Different Development Paths, Challenges and the Profiles of Three Repositioned Drugs” at the Strategic Partnerships in Drug Repurposing conference in…

Details
NeuroHealing

U.S. Patent Office Issues Patents in NeuroHealing’s NH004 Program

Newton, Massachusetts – September 2016. NeuroHealing Pharmaceuticals, a private, clinical stage company developing innovative drug treatments for specialty indications based on repositioning neurologically active compounds, announces that the United States Patent and Trademark Office (USPTO) has issued to NeuroHealing two patents entitled ““Methods and Compositions for Decreasing Saliva Production.” The first patent (US 9,198,897), with a…

Details
NeuroHealing

NeuroHealing Adds Leading Experts to NH02D Program Medical Advisory Board

Newton, Massachusetts – June 2015. NeuroHealing Pharmaceuticals, a private, clinical stage company developing innovative drug treatments for specialty indications based on repositioning neurologically active compounds, announces two additions to the Medical Advisory Board (MAB) to advise on the company’s NH02D program for the treatment of premature ejaculation (PE).  The MAB assists NeuroHealing in the scientific and…

Details
NeuroHealing

NeuroHealing to Present at World Orphan Drug Congress USA 2015

Newton, Massachusetts – April 2015.  NeuroHealing Pharmaceuticals, a private, clinical stage company developing innovative drug treatments for specialty indications based on repositioning neurologically active compounds announces that Neal M. Farber, Ph.D., Chief Executive Officer, will present an overview of NH001 at the World Orphan Drug Congress USA taking place at the Washington Hilton, Washington D.C., April…

Details
NeuroHealing